{
  "id": "nsclc-pd1-main",
  "display_name": "NSCLC PD-L1≥50% (Main)",
  "cohort": "NSCLC PD-L1 ≥ 50%, First Line, Q1 2023",
  "insight_type": "Treatment Patterns by Regimen",
  "summary": "Pembrolizumab monotherapy utilization is at 75% for eligible patients, slightly below NCCN guidelines recommendation of 85%.",
  "recommendation": "Consider increasing pembrolizumab monotherapy utilization for eligible patients with PD-L1 ≥ 50%.",
  "financial_impact": 120000,
  "financial_impact_description": "Increasing pembrolizumab monotherapy could save approximately $120,000 annually by avoiding unnecessary combination therapies.",
  "peer_financial_impact": 180000,
  "peer_financial_impact_description": "Your organization is slightly below peer performance, representing potential savings of $180,000 annually.",
  "action_steps": [
    "Review patient selection criteria for pembrolizumab monotherapy",
    "Conduct provider education on NCCN guidelines for PD-L1 ≥ 50% patients",
    "Implement pathway alerts for eligible patients"
  ],
  "peer_action_steps": [
    "Benchmark against top-performing organizations",
    "Develop a specific action plan to increase appropriate monotherapy use",
    "Monitor progress monthly"
  ],
  "chart_data": {
    "categories": ["Pembrolizumab", "Chemo+IO", "Chemo only", "Atezolizumab", "Other"],
    "values": [75, 15, 5, 3, 2],
    "peer_values": [82, 10, 3, 3, 2],
    "target_values": [85, 10, 0, 5, 0]
  },
  "drilldowns": [
    {
      "label": "View by Payer",
      "description": "Compare regimen utilization by payer type",
      "jsonFile": "nsclc-pd1-by-payer.json"
    }
  ]
} 